Emergent BioSolutions Inc. (NYSE:EBS) Stake Reduced by Values First Advisors Inc.

Values First Advisors Inc. trimmed its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 17.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 376,692 shares of the biopharmaceutical company’s stock after selling 79,516 shares during the quarter. Emergent BioSolutions comprises about 2.0% of Values First Advisors Inc.’s holdings, making the stock its 8th biggest holding. Values First Advisors Inc.’s holdings in Emergent BioSolutions were worth $3,601,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. SeaCrest Wealth Management LLC lifted its stake in Emergent BioSolutions by 3.2% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after acquiring an additional 3,705 shares during the period. Stifel Financial Corp bought a new position in Emergent BioSolutions during the 3rd quarter valued at about $96,000. FORA Capital LLC bought a new position in Emergent BioSolutions during the 3rd quarter valued at about $103,000. Hilltop Holdings Inc. lifted its stake in Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 12,515 shares during the period. Finally, Truist Financial Corp lifted its stake in Emergent BioSolutions by 12.3% during the 2nd quarter. Truist Financial Corp now owns 131,526 shares of the biopharmaceutical company’s stock valued at $897,000 after acquiring an additional 14,360 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Trading Down 4.4 %

Shares of NYSE:EBS opened at $9.66 on Wednesday. The firm’s 50 day moving average price is $9.66 and its 200-day moving average price is $9.23. Emergent BioSolutions Inc. has a twelve month low of $1.48 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Wall Street Analysts Forecast Growth

EBS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, January 21st. Benchmark increased their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Friday, January 24th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.